Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
ID: 349971Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349971

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-274.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to support the early evaluation of promising pharmacological interventions that target non-amyloid/non-tau mechanisms to address cognitive and neuropsychiatric symptoms across the Alzheimer's spectrum, combining Phase 1 clinical trials with Phase 1b/Phase 2a trials under a UG3/UH3 phased award mechanism. With the prevalence of Alzheimer's projected to exceed 12 million Americans by 2050, this funding opportunity is crucial for advancing clinical research and addressing the significant economic burdens associated with the disease. Interested applicants must submit their proposals by January 19, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-274-Full-Announcement.html
    PAR-23-274.html
    The Department of Health and Human Services is soliciting applications for a funding opportunity titled "Seamless Early-Stage Clinical Drug Development for Alzheimer's Disease (AD) and Related Dementias (ADRD)." The National Institutes of Health (NIH) aims to support the early evaluation of novel pharmacological interventions targeting non-amyloid/non-tau mechanisms to address cognitive and neuropsychiatric symptoms across the Alzheimer's spectrum. Eligible for funding are bundled clinical trials, combining Phase 1 with Phase 1b/Phase 2a trials within a UG3/UH3 phased award framework. Applications must specify safety and tolerability milestones to advance phases, with a submission deadline of January 19, 2024. The initiative targets the growing prevalence of AD, projected to affect over 12 million Americans by 2050, while addressing significant economic burdens. The NIH encourages diversity in research teams and emphasizes transparent data management and sharing for enhanced scientific collaboration. Lastly, the cooperative agreements emphasize substantial involvement from NIH staff, focusing on collective efforts to advance clinical research on AD therapies.
    Similar Opportunities
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.